Pacira | PCRX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Astellas Pharma JPY 455.56B 33.8B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cara Therapeutics USD 7.05M 1.11M 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
J&J USD 17.83B 388M 2026-06
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Novo Nordisk DKK 44.73B 7.52B 2026-06
Omeros USD 59.16M 20.13M 2024-06
Pacira USD 180.54M 7.79M 2026-06
Perrigo USD 290.5M 645.1M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Supernus Pharmaceuticals USD 1.03B 45.58M 2026-06
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Xeris Pharmaceuticals USD 75.21M 6.18M 2026-03
Zoetis USD 3.15B 85M 2026-06